Supplemental data

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes.

Condensed Consolidating Statements of Income



For the six months ended June 30, 2019	Consolidated Total			Physician Groups			Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Patient service operating revenues	$	5,369,217		$	—		$	—	$	5,369,217
Provision for uncollectible accounts	(15,712		)	—			—		(15,712		)
Net patient service operating revenues	5,353,505			—			—		5,353,505
Other revenues	232,312			—			—		232,312
Total net operating revenues	5,585,817			—			—		5,585,817
Operating expenses	4,783,424			—			—		4,783,424
Operating income	802,393			—			—		802,393
Debt expense	(275,345		)	—			—		(275,345		)
Other income	12,583			—			—		12,583
Income tax expense	132,684			—			—		132,684
Net income from continuing operations	406,947			—			—		406,947
Net income from discontinued operations, net of tax	109,697			12,706			249		96,742
Net income	516,644			12,706			249		503,689
Less: Net income attributable to noncontrolling interests	(93,804		)	(1,255		)	—		(92,549		)
Net income attributable to DaVita Inc.	$	422,840		$	11,451		$	249	$	411,140


(1)	After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Comprehensive Income



For the six months ended June 30, 2019	Consolidated Total			Physician Groups			Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Net income	$	516,644		$	12,706		$	249	$	503,689
Other comprehensive income	1,313			—			—		1,313
Total comprehensive income	517,957			12,706			249		505,002
Less: Comprehensive income attributable to the noncontrolling interests	(93,804		)	(1,255		)	—		(92,549		)
Comprehensive income attributable to DaVita Inc.	$	424,153		$	11,451		$	249	$	412,453


(1)	After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Balance Sheets



As of June 30, 2019	Consolidated Total		Physician Groups		Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Cash and cash equivalents	$	3,575,638	$	—	$	—	$	3,575,638
Restricted cash and equivalents	106,772		—		—		106,772
Accounts receivable, net	2,010,801		—		—		2,010,801
Other current assets	697,418		—		—		697,418
Total current assets	6,390,629		—		—		6,390,629
Property and equipment, net	3,405,315		—		—		3,405,315
Operating lease right-of-use assets	2,790,885		—		—		2,790,885
Amortizable intangibles, net	120,574		—		—		120,574
Other long-term assets	358,171		—		—		358,171
Goodwill	6,865,386		—		—		6,865,386
Total assets	$	19,930,960	$	—	$	—	$	19,930,960
Current liabilities	$	5,706,944	$	—	$	—	$	5,706,944
Long-term operating leases liabilities	2,689,249		—		—		2,689,249
Long-term debt and other long-term liabilities	6,105,965		—		—		6,105,965
Noncontrolling interests subject to put provisions	1,185,733		—		—		1,185,733
Total DaVita Inc. shareholders’ equity	4,049,298		—		—		4,049,298
Noncontrolling interests not subject to put provisions	193,771		—		—		193,771
Shareholders’ equity	4,243,069		—		—		4,243,069
Total liabilities and shareholder’s equity	$	19,930,960	$	—	$	—	$	19,930,960


(1)	After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Cash Flows



For the six months ended June 30, 2019	Consolidated Total			Physician Groups			Unrestricted Subsidiaries			Company and Restricted Subsidiaries⁽¹⁾
Cash flows from operating activities:
Net income	$	516,644		$	12,706		$	249		$	503,689
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	234,471			(4,607		)	(249		)	239,327
Net cash provided by operating activities	751,115			8,099			—			743,016
Cash flows from investing activities:
Additions of property and equipment	(373,918		)	(846		)	—			(373,072		)
Acquisitions	(65,970		)	—			—			(65,970		)
Proceeds from asset and business sales	3,851,381			—			—			3,851,381
Investments and other items	(8,801		)	(1,882		)	—			(6,919		)
Net cash provided by (used in) investing activities	3,402,692			(2,728		)	—			3,405,420
Cash flows from financing activities:
Long-term debt	(1,164,109		)	—			—			(1,164,109		)
Intercompany	—			(247,175		)	—			247,175
Other items	(146,444		)	—			—			(146,444		)
Net cash used in financing activities	(1,310,553		)	(247,175		)	—			(1,063,378		)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(77		)	—			—			(77		)
Net increase (decrease) in cash, cash equivalents and restricted cash	2,843,177			(241,804		)	—			3,084,981
Less: Net decrease in cash, cash equivalents and restricted cash from discontinued operations	(423,813		)	(241,804		)	—			(182,009		)
Net increase in cash, cash equivalents and restricted cash from continuing operations	3,266,990			—			—			3,266,990
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year	415,420			—			—			415,420
Cash, cash equivalents and restricted cash of continuing operations at end of the period	$	3,682,410		$	—		$	—		$	3,682,410

(1)

After elimination of the unrestricted subsidiaries and the physician groups.